Research and treatment approaches to depression

Nature Reviews Neuroscience

Volumn 2, Issue 5, 2001, Pages 343-351

  Wong, Ma Li ^a   Licinio, Julio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ANIMAL; BRAIN LEVEL; DEPRESSION; DRUG DESIGN; DRUG EFFECT; EPIDEMIOLOGY; GENETICS; HUMAN; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN CHEMISTRY; CAUSALITY; DEPRESSION; DRUG DESIGN; HUMANS;

EID: 0035348160     PISSN: 14710048     EISSN: None     Source Type: Journal    
DOI: 10.1038/35072566     Document Type: Review

References (101)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, Washington, DC, 1994).
2. Zis, A. P. & Goodwin, F. K. Major affective disorder as a recurrent illness: a critical review. Arch. Gen. Psychiatry 36, 835-839 (1979).
3. Sundstrom, I. M., Bixo, M., Bjom, I. & Astrom, M. Prevalence of psychiatric disorders in gynecologic outpatients. Am. J. Obstet. Gynecol. 184, 8-13 (2001).
4. Lyness, J. M., Caine, E. D., King, D. A., Cox, C. & Yoediono, Z. Psychiatric disorders in older primary care patients. J. Gen. Intern. Med. 14, 249-254 (1999).
5. Lindeman, S. et al. The 12-month prevalence and risk factors for major depressive episode in Finland: representative sample of 5993 adults. Acta Psychiatr. Scand. 102, 178-184 (2000).
6. Dubini, A., Mannheimer, R. & Pancheri, P. Depression in the community: results of the first Italian survey. Int. Clin. Psychopharmacol. 16, 49-53 (2001).
7. Fichter, M. M. et al. Prevalence of mental illness in Germany and the United States. Comparison of the Upper Bavarian Study and the Epidemiologic Catchment Area Program. J. Nerv. Ment. Dis. 184, 593-606 (1996).
8. Tomoda, A., Mori, K., Kimura, M., Takahashi, T. & Kitamura, T. One-year prevalence and incidence of depression among first-year university students in Japan: a preliminary study. Psychiatry Clin. Neurosci. 54, 583-588 (2000).
9. Weissman, M. M. et al. Cross-national epidemiology of major depression and bipolar disorder. J. Am. Med. Assoc. 276, 293-299 (1996). A detailed assessment of lifetime and annual rate depression prevalence In ten countries: Canada, France, Germany, Italy, Korea, Lebanon, New Zealand, Puerto Rico, Taiwan and the United States.
10. Blazer, D. G., Kessler, R. C., McGonagle, K. A. & Swartz, M. S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 151, 979-986 (1994).
11. Greenberg, P. E., Stiglin, L. E., Finkelstein, S. N. & Berndt, E. R. The economic burden of depression in 1990. J. Clin. Psychiatry 54, 405-418 (1993). Estimates that the total cost of depression In the United States was $43.7 billion per year In 1990.
12. Murray, C. J. L. & Lopez, A. D. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk factors in 1990 and Projected to 2020 (Harvard Univ. Press, Cambridge, Massachusetts, 1996).
13. Murphy, S. L. Deaths: Final data for 1998. National Vital Statistics Reports (CDC) 48, 1-106 (2000).
14. Olsson, G. I. & von Knorring, A. L. Adolescent depression: prevalence in Swedish high-school students. Acta Psychiatr. Scand. 99, 324-331 (1999).
15. klerman, G. L. in The Harvard Guide to Modern Psychiatry (ed. Nicholi, J.) 253-281 (Belknap/Harvard Univ. Press, Cambridge, 1978).
16. Kerr, T. A., Schapira, K. & Roth, M. The relationship between premature death and affective disorders. Br. J. Psychiatry 115, 1277-1282 (1969).
17. Harris, E. C. & Barraclough, B. Excess mortality of mental disorder. Br. J. Psychiatry 173, 11-53 (1998).
18. Pratt, L. A. et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 94, 3123-3129 (1996).
19. Glassman, A. H. & Shapiro, P. A. Depression and the course of coronary artery disease. Am. J. Psychiatry 155, 4-11 (1998). References 18 and 19 report that a history of depression Increases the risk of myocardial Infarction and the risk of death after Infarction.
20. Michelson, D. et al. Bone mineral density in women with depression. N. Engl. J. Med. 335, 1176-1181 (1996).
21. Agid, O. et al. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Mol. Psychiatry 4, 163-172 (1999). Shows that loss of a parent (mother more than father) before age nine is a significant predictor of depression later in life.
22. Nemeroff, C. B. The preeminent role of early untoward experience on vulnerability to major psychiatric disorders: the nature-nurture controversy revisited and soon to be resolved. Mol. Psychiatry 4, 106-108 (1999).
23. Lewis, A. J. Melancholia: a clinical survey of depressive states. J. Ment. Sci. 80, 277-378 (1934). A classic description of depression.
24. Garside, R. F., Kay, D. W., Wilson, I. C., Deaton, I. D. & Roth, M. Depressive syndromes and the classification of patients. Psychol. Med. 1, 333-338 (1971).
25. Gurland, B. Aims, organization, and initial studies of the Cross-Nafonal Project. Int. J. Aging Hum. Dev. 7, 283-293 (1976).
26. Katz, M. M., Secunda, S. K., Hirschfeld, R. M. & Koslow, S. H. NIMH clinical research branch collaborative program on the psychobiology of depression. Arch. Gen. Psychiatry 36, 765-771 (1979).
27. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnosis Guidelines (World Health Organization, Geneva, Switzerland, 1992).
28. Akiskal, H. S. Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin. J. Affect. Disord. 62, 17-31 (2001).
29. Seligman, M. E. Learned helplessness as a model of depression. Comment and integration. J. Abnorm. Psychol. 87, 165-179 (1978).
30. Seligman, M. E., Maier, S. F. & Geer, J. H. Alleviation of learned helplessness in the dog. J. Abnorm. Psychol. 73, 256-262 (1968).
31. Seligman, M. E., Rosellini, R. A. & Kozak, M. J. Learned helplessness in the rat: time course, immunization, and reversibility. J. Comp. Physiol. Psychol. 88, 542-547 (1975).
32. Kalin, N. H. & Carnes, M. Biological correlates of attachment bond disruption in humans and nonhuman primates. Prog. Neuropsychopharmacol. Biol. Psychiatry 8, 459-469 (1984).
33. Plotsky, P. M. & Meaney, M. J. Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res. Mol. Brain Res. 18, 195-200 (1993).
34. Blanchard, D. C. & Blanchard, R. J. Behavioral correlates of chronic dominance-subordination relationships of male rats in a seminatural situation. Neurosci. Biobehav. Rev. 14, 455-462 (1990). References 29-34 examine animal syndromes that model aspects of the depression phenotype.
35. Weissman, M. M. et al. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am. J. Psychiatry 136, 555-558 (1979).
36. Kovacs, M., Rush, A. J., Beck, A. T. & Hollon, S. D. Depressed outpatients treated with cognitive therapy or pharmacotherapy. A one-year follow-up. Arch. Gen. Psychiatry 38, 33-39 (1981). References 35 and 36 show that brief, structured psychotherapies are effective in the treatment of depression, and that they can be successfully combined with pharmacological treatments.
37. Nobel Foundation. Nobel Lectures - Physiology or Medicine, 1901-1970 (Elsevier, Amsterdam, 1970).
38. Bunney, W. E. & Davis, J. M. Noradrenaline in depressive reactions. A review. Arch. Gen. Psychiatry 13, 483-494 (1965).
39. Schildkraut, J. J., Gordon, E. K. & Durell, J. Catecholamine metabolism in affective disorders. I. Normetanephrine and VMA excretion in depressed patients treated with imipramine. J. Psychiatr. Res. 3, 213-228 (1965).
40. Coppen, A. The biochemistry of affective disorders. Br. J. Psychiatry 113, 1237-1264 (1967).
41. Delgado, P. L. et al. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 47, 411-418 (1990).
42. Miller, H. L. et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch. Gen. Psychiatry 53, 117-128 (1996).
43. Charney, D. S. Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry 59, 11-14 (1998). References 41-43 show that noradrenaline-and serotonin-selective probes can potentially identify subsets of depressed patients who might respond differentially to selective noradrenaline or serotonin reuptake inhibitors.
44. Thase, M. E. Frank, E. & Kupfer, D. J. in Handbook of Depression: Treatment, Assessment, and Research (eds Beckham, E. E. & Leber, W. R.) 816-913 (Dorsey, Homewood, Illinois, 1985).
45. Veith, R. C. et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alerations in plasma noradrenaline kinetics. Arch. Gen. Psychiatry 51, 411-422 (1994).
46. Wong, M. L. et al. Pronounced and sustained central hypemoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc. Natl Acad. Sci. USA 97, 325-330 (2000). References 45 and 46 report increased activity of sympathetic systems in depression.
47. Siever, L. J. & Davis, K. L. Overview: toward a dysregulation hypothesis of depression. Am. J. Psychiatry 142, 1017-1031 (1985).
48. Johnstone, E. C. et al. Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychol. Med. 10, 321-328 (1980).
49. Sachar, E. J., Hellman, L., Fukushima, D. K. & Gallagher, T. F. Cortisol production in depressive illness: a clinical and biochemical clarification. Arch. Gen. Psychiatry 23, 289-298 (1970).
50. Spiess, J., Rivier, J., Rivier, C. & Vale, W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc. Natl Acad. Sci. USA 78, 6517-6521 (1981).
51. Gold, P. W. et al. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am. J. Psychiatry 141, 619-627 (1984).
52. Nemeroff, C. B. et al. Elevated concentrations of CSF corticotropin-releasing-factor-like immunoreactivity in depressed patients. Science 226, 1342-1344 (1984).
53. Holsboer, F., Girken, A., Stalia, G. K. & Muller, O. A. Blunted corticotropin and normal Cortisol response to human corticotropin-releasing factor in depression. N. Engl. J. Med. 311, 1127 (1984).
54. Gold, P. W. et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N. Engl. J. Med. 314, 1329-1335 (1986).
55. Gold, P. W., Wong, M. L. Chrousos, G. P. & Licinio, J. Stress system abnormalities in melancholic and atypical depression: molecular, pathophysiological, and therapeutic implications. Mol. Psychiatry 1, 257-264 (1996).
56. Demitrack, M. A. et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J. Clin. Endocrinol. Metab. 73, 1224-1234 (1991).
57. Whybrow, P. C. & Prange, A. J., Jr. A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch. Gen. Psychiatry 38, 106-113 (1981).
58. Gold, P. W. & Chrousos, G. P. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc. Assoc. Am. Physicians 111, 22-34 (1999).
59. Whybrow, P. C., Coppen, A., Prange, A. J. Jr, Noguera, R. & Bailey, J. E. Thyroid function and the response to liothyronine in depression. Arch. Gen. Psychiatry 26, 242-245 (1972).
60. Joffe, R. T. Refractory depression: treatment strategies, with particular reference to the thyroid axis. J. Psychiatry Neurosci. 22, 327-331 (1997).
61. Kramer, M. S. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640-1645 (1998).
62. Zobel, A. W. et al. Effects of the high-affinity corticotropin-reteasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34, 171-181 (2000).
63. Kupfer, D. J., Shaw, D. H., Ulrich, R., Coble, P. A. & Spiker, D. G. Application of automated REM analysis in depression. Arch. Gen. Psychiatry 39, 569-573 (1982). Documents decreased latency to rapid-eye-movement-sleep onset in depressed patients.
64. Gerner, R. H., Post, R. M., Gillin, J. C. & Bunney, W. E. Jr Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals. J. Psychiatr. Res. 15, 21-40 (1979).
65. Lipkin, W. I., Travis, G. H., Carbone, K. M. & Wilson, M. C. Isolation and characterization of Borna disease agent cDNA clones. Proc. Natl. Acad. Sci. USA 87, 4184-4188 (1990).
66. Rott, R. et al. Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science 228, 755-756 (1985).
67. Bode, L., Zimmermann, W., Ferszt, R., Steinbach, F. & Ludwig, H. Borna disease virus genome transcribed and expressed in psychiatric patients. Nature Med. 1, 232-236 (1995).
68. Bode, L, Durrwald, R., Rantam, F. A., Ferszt, R. & Ludwig, H. First isolates of infectious human Borna disease virus from patients with mood disorders. Mol. Psychiatry 1, 200-212 (1996).
69. De La Torre, J. C. et al. Detection of borna disease virus antigen and RNA in human autopsy brain samples from neuropsychiatric patients. Virology 223, 272-282 (1996).
70. Kim, Y. K. et al. Failure to demonstrate Borna disease virus genome in peripheral blood mononuclear cells from psychiatric patients in Korea. J. Neurovirol. 5, 196-199 (1999).
71. Tsuji, K., Toyomasu, K., Imamura, Y., Maeda, H. & Toyoda, T. No association of borna disease virus with psychiatric disorders among patients in northern Kyushu, Japan. J. Med. Virol. 61, 336-340 (2000). References 65-71 report that Boma-disease virus (BDV) might infect a small, but significant portion of patients with depression; however, these findings have not been fully replicated. A causal relation between depression and BDV is at present unclear.
72. Solomon, G. F. Psychoneuroimmunology: interactions between central nervous system and immune system. J. Neurosci. Res. 18, 1-9 (1987).
73. Stemberg, E. M. Emotions and disease: from balance of humors to balance of molecules. Nature Med. 3, 264-267 (1997).
74. Licinio, J., Wong, M. L. & Gold, P. W. Localization of interieukin-1 receptor antagonist mRNA in rat brain. Endocrinology 129, 562-564 (1991).
75. Rothwell, N. J. & Hopkins, S. J. Cytokines and the nervous system II: Actions and mechanisms of action. Trends Neurosci. 18, 130-136 (1995).
76. Van Wagoner, N. J. & Benveniste, E. N. Interteukin-6 expression and regulation in astrocytes. J. Neuroimmunol. 100, 124-139 (1999).
77. Rothwell, N. J. & Luheshi, G. N. Interieukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci. 23, 618-625 (2000).
78. Connor, T. J. & Leonard, B. E. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62, 583-606 (1998).
79. Weiss, J. M., Sundar, S. K., Becker, K. J. & Cierpial, M. A. Behavioral and neural influences on cellular immune responses: effects of stress and interieukin-1. J. Clin. Psychiatry 50, S43-S53 (1989).
80. Buckingham, J. C., Loxley, H. D., Taylor, A. D. & Flower, R. J. Cytokines, glucocorticoids and neuroendocrine function. Pharmacol. Res. 30, 35-42 (1994).
81. Rivier, C. Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat. Ann. NY Acad. Sci. 697, 97-105 (1993).
82. Ramamoorthy, S. et al. Regulation of the human serotonin transporter by interteukin-1β. Biochem. Biophys. Res. Commun. 216, 560-567 (1995).
83. Maes, M. et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 9, 853-858 (1997).
84. Wong, M. L., Bongiomo, P. B., Rettori, V., McCann, S. M. & Licinio, J. Interieukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysioiogical implications. Proc. Natl Acad. Sci. USA 94, 227-232 (1997). Shows that central and peripheral cytokine compartments are integrated but differentially regulated: central cytokines are counter-regulated to a smaller extent than peripherally secreted ones.
85. Licinio, J. & Wong, M. L. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol. Psychiatry 4, 317-327 (1999).
86. Lander, E. S. & Schork, N. J. Genetic dissection of complex traits. Science 265, 2037-2048 (1994).
87. Fava, M. & Kendler, K. S. Major depressive disorder. Neuron 28, 335-341 (2000).
88. Sullivan, P. F., Neale, M. C. & Kendler, K. S. Genetic epidemiology of major depression: review and meta-analysis. Am. J. Psychiatry 157, 1552-1562 (2000). Shows that depression is caused by both genetic and environmental factors.
89. Kendler, K. S., Neale, M. C., Kessler, R. C., Heath, A. C. & Eaves, L. J. The lifetime history of major depression in women. Reliability of diagnosis and heritability. Arch. Gen. Psychiatry 50, 863-870 (1993). Shows that major depression as assessed over one's lifetime might be a rather highly heritable disorder of moderate reliability rather than a moderately heritable disorder of high reliability.
90. Lesch, K. P. et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527-1531 (1996). Discovery of a polymorphism in the regulatory region of the serotonin transporter gene that reduces transcriptional efficiency and might be correlated with anxiety traits.
91. Smeraldi, E. et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 3, 508-511 (1998). Proposes that genotyping the serotonin transporter regulatory region might be used as a tool to predict treatment response in depression.
92. Kim, D. K. et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11, 215-219 (2000).
93. Benedetti, F. et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am. J. Psychiatry 156, 1450-1452 (1999).
94. Wong, M. L., Khatri, P., Licinio, J., Esposito, A. & Gold, P. W. Identification of hypothalamic transcripts upregulated by antidepressants. Biochem. Biophys. Res. Commun. 229, 275-279 (1996).
95. Hyman, S. E. Mental illness. Genetically complex disorders of neural circuitry and neural communication. Neuron 28, 321-323 (2000). Reviews the complexity of depression genetics.
96. Selye, H. A syndrome produced by diverse nocuous agents. Nature 138, 32 (1936). In this one-page article, Selye launched the field of stress biology. He showed that the organism had common responses to various types of stressor, and described those responses as much as it was possible using the methods available to him in the 1930s.
97. Chrousos, G. P. & Gold, P. W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. J. Am. Med. Assoc. 267, 1244-1252 (1992).
98. Brady, L. S., Whitfield, H. J. Jr, Fox, R. J., Gold, P. W. & Herkenham, M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J. Clin. Invest. 87, 831-837 (1991).
99. Brady, L. S., Gold, P. W., Herkenham, M., Lynn, A. B. & Whitfield, H. J. Jr The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res. 572, 117-125 (1992).
100. Michelson, D. et al. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J. Clin. Endocrinol. Metab. 82, 2601-2606 (1997). References 98-100 show that attenuation of hypothalamus-pituitary-adrenal axis activity is a direct pharmacological effect of antidepressants.
101. Habib, K. E. et al. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autoncmic responses to stress in primates. Proc. Natl Acad. Sci. USA 97, 6079-6084 (2000).